Skip to main content
. Author manuscript; available in PMC: 2011 Apr 1.
Published in final edited form as: Pediatr Blood Cancer. 2010 Apr;54(4):596–602. doi: 10.1002/pbc.22344

Table II.

Patient Characteristics

Level Age
(months),
Gender
Wt
(kg)
Disease
Sites
Histology31
/MYCN
Adequate
PBSC
Yield
(Yes/No)
DLT
(cycle/harvest
# occurred)
BM
Status
Cycle
2
PBSC
Immuno
(# pos
/tested)
Response
End
Induction
I
Response
End
Induction
II
EFS
1 20, M 11 A, BM,
B
UH/ND Yes PLT (1, 2) Pos 0/3 PR Off DOD
1 31, M 13.7 A, BM,
B
UH/ amp Yes - Neg 0/3 PR CR* DOD
1 60,F 17.2 A, BM,
B
ND No PLT (1)
PBSC (1)
Neg 0/5 PR off CCR
1 25, M 10.4 A, B,
LN
UH/ amp Yes - Neg 0/2 PR PR DOT+
1 54, M 14.8 A, BM,
B, LN
ND Yes PLT (2, 3) Pos 0/3 PR PD DOD
1 14, M 10.2 A, BM,
B
ND N/A N/A Pos N/A PD - DOD
1 15, M 13 C, BM,
B
FH/ amp No PLT (1)
PBSC (2)
Neg 0/5 PR off DOD
1 93, F 21.7 RP,
BM, B,
LN
ND/ non No PBSC (2) Neg 0/4 PR off CCR
0 32,M 17.3 A, BM,
B, LN,
L
ND Yes PLT (1) Pos 0/1 MR PD after
Cycle 5
DOD
0 35, F 16 A, BM,
B, L,
LN
ND Yes PLT (3) Pos 0/4 PR PR DOD
0 31, M 11.2 C, BM,
B
UH/ amp Yes - Neg 0/2 MR PR DOD
0 106, M 25.4 A, BM,
B, LN
ND Yes - Neg ND MR VGPR DOD
0 20, M 17 A, RP,
BM, B,
L
UH/ amp No PLT (3)
PBSC (3)
Neg 0/2 SD MR DOD
0 39, M 16 A, BM,
B
UH/ non Yes - Pos 0/2 MR MR DOD
0 38, M 15.2 A, BM,
B, LN
UH/ non Yes PLT (3) Neg 0/6 PR CR* DOD
0A 50, M 15.9 A, BM,
B, L
UH/ non Yes - Pos ND MR PR DOD
0A 20, F 10 A, BM,
B, L
UH/ non Yes PLT (2, 3) Neg ND SD PR DOD
0A 29, F 12.9 A, BM,
B
FH/ non Yes - Neg ND PR CR CCR
0A 35, M 13.5 A, BM,
B
UH/ amp Yes PLT (3) Neg 0/3 PR PR CCR
0A 25, M 14 RP, LN UH/ ND Yes PLT (2, 3) Neg ND PR VGPR CCR
0A 36, M 14.5 A, BM,
B
UH/ND Yes - Pos ND PR VGPR DOD
0A 46, F 13.7 A, BM,
B,LN
UH/ ND Yes - Pos 0/1 PR PR CCR

A= adrenal primary, C= celiac primary, RP=retroperitoneal primary, BM= bone marrow, B= bone, LN= lymph node, FH= favorable Shimada histology, UH= unfavorable Shimada histology, amp = amplified MYCN, non= non-amplified MYCN, PLT = dose limiting toxicity of plateletrecovery, PBSC= dose limiting toxicity of inadequate PBSC collection, DOD = dead of disease, DOT= dead of toxicity, N/A= not applicable, ND= not done.

*

patients not evaluated for response until after surgery for local control

+

patient died of toxicity (pneumonia) during non protocol BMT one month after completing protocol therapy.